Nathalie Guffon
307 works · 10,339 citations · h-index 47
Top works
- Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
- Long-Term Safety and Efficacy of Enzyme Replacement Therapyfor Fabry Disease
- Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
- Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase β Therapy in Patients with Fabry Disease
- Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
- Follow-up of nine patients with Hurler syndrome after bone marrow transplantation
- Enzyme Replacement Therapy in Patients Who Have Mucopolysaccharidosis I and Are Younger Than 5 Years: Results of a Multinational Study of Recombinant Human α- l -Iduronidase (Laronidase)
- The MPS I registry: Design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I
- Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
- Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources
- NTBC treatment in tyrosinaemia type I: Long‐term outcome in French patients
- Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase
- Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
- Multidisciplinary Management of Hunter Syndrome
- Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease
- NovelOCTN2mutations: No genotype–phenotype correlations: Early carnitine therapy prevents cardiomyopathy
- Safety and Efficacy of Enzyme Replacement Therapy with Agalsidase Beta: An International, Open-label Study in Pediatric Patients with Fabry Disease
- The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects
- Natural history of Niemann-Pick disease type C in a multicentre observational retrospective cohort study
- Mutational analysis of 105 mucopolysaccharidosis type VI patients